S4-E10.4 - Pediatric and Adolescent Fatty Liver: Impact of Emerging Drugs and Trials

Send us Fan MailIn yet another topical debut, Surfing NASH explores pediatric and adolescent Fatty Liver disease, its alarming incidence rate and developing the field's understanding around how to treat a vulnerable subpopulation. The Surfers are joined in discussion by Naim Alkhouri and chief of Gastroenterology, Hepatology and Nutrition at Children’s Hospital Los Angeles, Rohit Kohli, for a special session which illuminates a public health crisis intimate to the two extremely knowledgeable guests.Roger Green leads this final conversation with an apt metaphor. He suggests that a population facing increasing severity downstream is like dealing with a momentous snowball rolling downhill and amassing trouble. With this in mind, he asks the panelists where they think we have the ability in advance of drug trials for pediatrics to intervene and either slow or ideally eviscerate the snowball. Rohit responds that it depends on the slope of the hill, and every child, because of underlying genetics and environmental influences, has a different slope. Both Jörn Schattenberg and Naim describe this as an arena of prevention. Finally, Louise Campbell raises grave concern over coping with the enormous industry influence on the milieu of nutrition surrounding children.If you have questions or interest around pediatric and adolescent Fatty Liver disease, we kindly ask that you submit reviews wherever you download our discussions. Alternatively, you can write us directly at [email protected] Safe and Surf On!